Sign in Subscribe
Diseases

Peritransplant Lysine Methyltransferase 2a-Rearranged Measurable Residual Disease Dynamics as a Prognostic Marker in Adult Acute Myeloid Leukemia

Strategic Insights

— 1 min read

A study published in the journal Cancer has shed light on the impact of measurable residual disease (MRD) dynamics in adults with lysine methyltransferase 2a rearrangement (KMT2Ar) in acute myeloid leukemia (AML) during the peritransplant period. The research, conducted by a team from Peking University People's Hospital, involved 144 adult patients with AML and KMT2Ar who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between 2015 and 2024. The study found that peritransplant MRD dynamics confer superior prognostic accuracy compared to single-time point MRD assessments.

Key Takeaways:

  • The study involved 144 adult patients with AML and KMT2Ar who underwent HSCT between 2015 and 2024.
  • Patients were enrolled if they survived without relapse for at least 3 months post-HSCT.
  • MRD was measured via real-time quantitative polymerase chain reaction, and the cohort was categorized into four groups based on MRD status before and after HSCT.
  • Significant differences were found in 3-year overall survival (OS), leukemia-free survival (LFS), and cumulative incidence of relapse (CIR).
  • The research concluded that peritransplant MRD dynamics confer superior prognostic accuracy.

Statistics:

  • 144 adult patients with AML and KMT2Ar were involved in the study.
  • 81 patients were MRD negative/MRD negative.
  • 2 patients were MRD negative/MRD positive.
  • 43 patients were MRD positive/MRD negative.
  • 18 patients were MRD positive/MRD positive.

Sources:

  • Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia. Cancer, 2025;131(16).
  • NewsRx. Data from Peking University People's Hospital Advance Knowledge in Acute Myeloid Leukemia (Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia). Hematology Week. August 25, 2025; p 372.

Read more